WebDoctor Encyclopedia

Head & neck Soft-tissue sarcomas

Biphenotypic sinonasal sarcoma

Biphenotypic sinonasal sarcoma is a rare, slow-growing sarcoma of the upper nose and ethmoid sinuses, driven by a PAX3 gene fusion. It mostly affects middle-aged women, often recurs locally but almost never spreads, and is treated mainly with endoscopic surgery.

Medically reviewed Last reviewed October 20, 2026

What is biphenotypic sinonasal sarcoma?

Biphenotypic sinonasal sarcoma (BSNS) is an uncommon cancer of the nose and sinuses that grows slowly. It belongs to the group of soft-tissue sarcomas, which are cancers of connective tissue. “Biphenotypic” means its cells show two kinds of features at once: some resemble nerve-sheath cells and some resemble muscle cells. It was first described as a separate disease only in 2012 and was originally called low-grade sinonasal sarcoma with neural and myogenic features.

BSNS almost always starts high in the nasal cavity or in the ethmoid sinuses, the honeycomb of small air spaces between the eyes. It mainly affects adults in middle age, and women are affected about twice as often as men.

The tumour is caused by a change in a gene called PAX3, which becomes fused to another gene, most often MAML3 (Wang et al., 2014). This gene change is so typical that testing for it helps confirm the diagnosis.

BSNS is described as low grade. It can grow into nearby structures such as the eye socket and the base of the skull, and it often comes back after surgery if not fully removed. However, spread to distant organs is extremely rare and deaths from the disease are uncommon (Carter, East and McHugh, 2018). Surgery, often by endoscopic (keyhole) techniques through the nose, is the main treatment.

1. Key facts at a glance

Feature Details
Type of cancer Low-grade spindle cell sarcoma of the nose and sinuses
Former name Low-grade sinonasal sarcoma with neural and myogenic features
How common Very rare; a few hundred cases reported since 2012
Typical age Adults, average around 50; wide range
Sex About twice as common in women
Main sites Upper nasal cavity and ethmoid sinuses
Key gene change PAX3 fusion, most often PAX3::MAML3
Main treatment Surgical removal, sometimes followed by radiotherapy
Outlook Good survival; local recurrence is common

2. Types of biphenotypic sinonasal sarcoma

All BSNS tumours share the same basic appearance, but they differ in the partner gene fused to PAX3.

Fusion Notes
PAX3::MAML3 The most frequent; found in the majority of cases
PAX3::FOXO1 Less common; also seen in alveolar rhabdomyosarcoma, a different cancer
PAX3::NCOA1 or PAX3::NCOA2 Rare; some show areas of muscle-type (rhabdomyoblastic) differentiation
Other partners Occasional rare fusions, such as WWTR1 or FOXO6

A very small number of tumours have been reported to change into a high-grade sarcoma, but this is exceptional.

How it differs from other nose and sinus cancers

Feature BSNS Common sinonasal carcinomas
Cell type Spindle cells (sarcoma) Lining cells (carcinoma)
Link with smoking or wood dust None known Often present
Spread to lymph nodes Almost never Possible
Growth Slow Often faster
Main risk Local recurrence Local and distant spread

Understanding the nose and sinuses

Structure Role and relevance to BSNS
Nasal cavity The air passage behind the nose; the upper part is the most frequent starting point
Ethmoid sinuses Small air cells between the eyes; very often involved
Frontal sinus Above the eyes; may be blocked by the tumour
Maxillary sinus In the cheek; involved less often
Eye socket (orbit) Separated from the ethmoid sinuses by a paper-thin bone
Skull base (cribriform plate) The thin roof of the nose, below the front of the brain; carries the nerves of smell

Because the bone between the sinuses, the eye socket and the brain is so thin, even a slow-growing tumour can reach these areas before it causes obvious symptoms.

3. Causes and risk factors

The cause of BSNS is not known. The PAX3 fusion arises in the tumour cells during life. PAX3 normally helps guide the development of nerve and muscle tissue in the embryo, which explains why the tumour cells show features of both (Wang et al., 2014).

Factor Notes
Female sex Women are affected more often
Middle age Most patients are in their 40s to 60s
Environmental exposures No clear link with smoking, wood dust or chemicals
Inherited conditions None known

The gene change is not inherited and cannot be passed on.

4. How does it look

From the outside

Usually there is nothing visible. Large tumours may cause swelling around the eye or a bulging eye.

Inside the nose

Feature Description
Appearance A pink, fleshy, polyp-like mass
Surface Usually smooth, covered by normal nasal lining
Position High in the nasal cavity or ethmoid sinuses
Bleeding May bleed when touched
Mistaken for An ordinary nasal polyp

On scans

CT shows how the tumour has affected the thin bones of the sinuses, eye socket and skull base. Bone may be thinned, pushed or thickened rather than aggressively destroyed. MRI shows the tumour’s extent into the eye socket, brain coverings and skull base, and helps distinguish tumour from trapped mucus.

Under the microscope

Feature Description
Cells Uniform, slender spindle cells arranged in long bundles
Pattern Herringbone or interlacing fascicles
Blood vessels Thin-walled, branching vessels
Surface lining Often shows invaginations of the overlying epithelium
Stains S100 and smooth muscle actin positive; PAX3 positive
Molecular test Detects the PAX3 fusion

PAX3 staining is highly sensitive and specific for BSNS, helping to separate it from similar-looking tumours (Jo et al., 2018).

5. Symptoms

Common symptoms

  • A blocked nose, often on one side, that does not clear
  • Nosebleeds
  • Pressure or pain around the nose, forehead or eyes
  • Reduced sense of smell
  • Headache

Less common symptoms

Symptom What it may mean
Watery eye Blockage of the tear duct
Double vision or bulging eye Growth into the eye socket
Swelling between the eyes Local growth
Clear fluid from the nose Rarely, a leak of brain fluid through the skull base
Facial numbness Nerve involvement

When to seek medical advice

See a doctor if you have a blocked nose on one side that lasts for weeks, repeated nosebleeds, or changes in your vision or eye position. Most of these symptoms are caused by common conditions, but one-sided symptoms should be checked by an ear, nose and throat (ENT) specialist.

6. Diagnosis

Test Purpose
Nasal endoscopy A thin camera examines the inside of the nose
Biopsy Tissue sample, usually taken in clinic or under anaesthetic
Immunohistochemistry S100, smooth muscle actin and PAX3 stains
Molecular testing Confirms the PAX3 fusion
CT of the sinuses Shows bony changes
MRI of the head Shows spread to the eye socket and skull base
Eye examination If the eye socket may be involved

Conditions that can look similar

Condition Notes
Nasal polyp Common and benign; may look identical on examination
Schwannoma Benign nerve sheath tumour
Malignant peripheral nerve sheath tumour A more aggressive sarcoma
Synovial sarcoma Another spindle cell sarcoma
Solitary fibrous tumour or glomangiopericytoma Other sinonasal soft-tissue tumours

Staging

There is no specific staging system. Doctors describe the extent of local spread, especially into the eye socket, skull base or brain coverings, because this determines the surgical approach.

7. Treatment

Treatment is planned by a skull base or head and neck team, usually including ENT surgeons, neurosurgeons, ophthalmologists and clinical oncologists.

Surgery

Approach When it is used
Endoscopic endonasal surgery Most tumours; removed through the nostrils with a camera
Endoscopic transnasal craniectomy When the tumour reaches the skull base; the skull base is repaired afterwards
Combined cranio-endoscopic approach When the tumour extends into the skull
Open approaches Occasionally for very large tumours

The goal is complete removal with clear margins. In a European series of 15 patients treated by endoscopic-assisted approaches, all were alive at 5 years, and about 80% were free of disease (Turri-Zanoni et al., 2022).

Radiotherapy

Situation Role
Positive or close margins May lower the risk of recurrence
Tumours that cannot be fully removed For local control
Recurrent disease After further surgery, or instead of it

Modern techniques such as intensity-modulated radiotherapy or proton therapy help protect the eyes, optic nerves and brain.

Drug treatment

Chemotherapy has no established role. Research into the PAX3 fusion may lead to targeted treatments in the future.

Side effects

Treatment Possible side effects
Endoscopic surgery Crusting, nasal blockage, bleeding, reduced sense of smell
Skull base surgery Small risk of brain fluid leak or infection
Radiotherapy Dryness and crusting in the nose, tiredness, dry eye; rarely, vision problems

What treatment involves day to day

Stage What to expect
Endoscopic surgery Usually 1-3 nights in hospital
Recovery Nasal rinses several times a day for weeks
Skull base repair Avoid nose-blowing, straining and heavy lifting for several weeks
Radiotherapy, if needed Weekday sessions for about 5-6 weeks

Recovery after endoscopic surgery

Time after surgery What is typical
First week Blocked nose, mild bleeding, tiredness; avoid blowing the nose
Weeks 2-4 Crusting gradually eases with rinses; clinic visit to clean the nose
Weeks 4-8 Most people return to normal activities and work
Months 3-6 Healing usually complete; first follow-up scan

Your sense of smell may improve, stay the same or worsen, depending on how close the tumour was to the smell nerves.

8. Outlook (prognosis)

Measure Usual result
Survival Very high; deaths from BSNS are rare
Local recurrence Common, sometimes many years after treatment
Distant spread Exceptionally rare
Most important factor Complete removal with clear margins

Recurrences can usually be treated with further surgery or radiotherapy. Because the tumour grows slowly, recurrences may appear late, so long-term follow-up is advised (Carter, East and McHugh, 2018).

9. Follow-up

Follow-up Purpose
Nasal endoscopy every 3-6 months at first Looks directly for recurrence
MRI Often every 6-12 months, then less frequently
Eye and vision checks If the eye socket was involved or treated
Long-term follow-up Usually 10 years or more because of late recurrence

10. Living with biphenotypic sinonasal sarcoma

  • Use saline nasal rinses as advised to keep the nose clean
  • Report new nasal blockage, bleeding or eye changes
  • Attend all scans and endoscopies, even if you feel well
  • Protect your eyes with lubricating drops if they become dry after radiotherapy
  • Avoid smoking, which slows healing of the nasal lining
  • Use a humidifier at night if your nose feels dry and crusted
  • Tell any new doctor about your diagnosis, as follow-up may span many years
  • Seek support from sarcoma and head and neck cancer charities

11. Frequently asked questions

Question Answer
Is it a serious cancer? It is a low-grade cancer; it can grow locally but rarely spreads
Is it caused by smoking? No link has been found
Is it inherited? No
Will I need chemotherapy? Generally not
Can it come back? Yes, which is why long-term follow-up is important
Will I lose my sense of smell? It may be reduced, depending on the tumour’s position and the surgery
Can surgery be done through the nose? In most cases, yes
Will I have a scar on my face? Not usually with endoscopic surgery
How quickly does it grow? Slowly, often over years
Can I fly after surgery? Usually after a few weeks; ask your surgeon, especially after skull base repair

12. Questions to ask your care team

  • How far has the tumour spread into the eye socket or skull base?
  • Can it be removed endoscopically?
  • Were the margins clear?
  • Do I need radiotherapy?
  • Which fusion gene does my tumour have?
  • How long will my follow-up last?
  • What will happen to my sense of smell?
  • Is this centre experienced in skull base surgery?

Resources

  1. Carter, C.S., East, E.G. and McHugh, J.B. (2018) ‘Biphenotypic sinonasal sarcoma: a review and update’, Archives of Pathology and Laboratory Medicine, 142(10), pp. 1196-1201.
  2. Jo, V.Y. et al. (2018) ‘Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics’, American Journal of Surgical Pathology, 42(10), pp. 1275-1285.
  3. Turri-Zanoni, M. et al. (2022) ‘Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review’, Acta Otorhinolaryngologica Italica, 42(6), pp. 545-553.
  4. Wang, X. et al. (2014) ‘Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma’, Nature Genetics, 46(7), pp. 666-668.
  5. National Cancer Institute (2026) Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/paranasal-sinus-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.